{"entity":{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","aka":[],"tldr":"Leads the world's highest-volume breast cancer surgical unit and the FUTURE trial that treats triple-negative breast cancer by molecular subtype.","summary":"Zhi-Ming Shao is Professor of Breast Surgery and Director of the Department of Breast Surgery at Fudan University Shanghai Cancer Center, the world's highest-volume breast cancer surgical unit. His group defined the Fudan classification of triple-negative breast cancer into four molecular subtypes using genomic profiling and RNA sequencing, and tested subtype-directed therapy in the FUTURE umbrella trial, which produced response rates far above conventional chemotherapy in refractory disease. His publications include the molecular subtyping and genomic profiling study that exposed precision therapy strategies in triple-negative breast cancer, and the FUTURE phase 2 umbrella trial in heavily pretreated metastatic disease. His interests are subtyping, precision oncology and umbrella trials.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shao%20ZM%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["cgp","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Surgery; Director, Department of Breast Surgery, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Breast cancer surgery","Triple-negative breast cancer subtyping","Precision oncology","Umbrella trials"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shao%20ZM%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan"}],"papers":[{"title":"Molecular subtyping and genomic profiling expose precision therapy strategies in triple-negative breast cancer","journal":"Cancer Cell","year":2019,"doi":"10.1016/j.ccell.2019.02.001"},{"title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial","journal":"Cell Research","year":2023,"doi":"10.1038/s41422-023-00795-2"},{"title":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1814017","doi":"10.1056/NEJMoa1814017"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0002-4503-148X"},"route":"/people/shao-zhi-ming/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"institution":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/"}],"term":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/"}],"paper":[{"id":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","kind":"paper","name":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","route":"/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/"},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/"},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"}]}}